Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc. demonstrated a robust financial performance with a significant 47% year-over-year increase in operating income, reaching $18.8 million, complemented by a strong adjusted gross margin of 70.4%. The company reported an impressive 14% organic revenue growth driven by a combination of 9% price and 5% volume increases, while adjusted EPS rose by 23%. Additionally, regional sales exhibited strong momentum, particularly in EMEA and APAC markets, further strengthening the overall growth outlook for the company.

Bears say

LeMaitre Vascular Inc faces a challenging outlook due to potential technical problems with its mRidium pump, unexpected competition, and possible regulatory issues with the FDA that could significantly impair financial performance. Additionally, the company has identified risks such as lower price increases, competitive pressures, slower international market adoption, and delays in regulatory approvals that may negatively influence its financial position. Finally, while general and administrative expenses were slightly lower than expected at 16.1% of revenue, any failure to meet revenue forecasts could adversely affect the company's shares.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.